Nicola Dagg is a partner in the Intellectual Property Team in the London office of Kirkland & Ellis International LLP. Nicola’s practice spans four areas:
► (1) strategic patent and product lifecycle advice;
► (2)patentlitigation;
► (3)co-ordinatingglobalIPenforcement/defencecases;and ► (4)standardessentialpatent(SEP)andFRANDdisputes.
Nicola has extensive experience on all aspects of intellectual property advisory and litigation work, including blockbuster small molecule litigation against generic companies, biologics and biosimilar litigation, antibodies, immunotherapies, genetics, vaccines, diagnostics and gene therapies. Nicola also acts in market leading SEP essentiality, validity and global FRAND adjudication litigation in the tech sector. Having served as UK and European/global co-ordinating counsel for numerous strategic IP projects litigation cases and drawing on almost 30 years of legal, IP, life sciences and tech experience she helps clients solve their most pressing global IP challenges.
Nicola is ranked as a leading Tier 1 IP partner in Chambers Global, Chambers UK, JUVE Patent and The Legal 500. Chambers UK 2024 recognises Nicola as a “top-notch leader” who is “extremely intelligent, thoughtful, creative and business-savvy”.
Nicola has consistently been recognised as a gold-ranked patent litigator by IAM Patent 1000 and in their 2023 directory they describe her as “a fearsome practitioner respected by all in the market... she delivers top quality strategic advice”.
The Legal 500 UK named Nicola a “Hall of Fame” attorney in the Intellectual Property Patents category, as well as a leading individual in Life Sciences and Healthcare. The 2024 edition refers to Nicola as “one of the outstanding patent litigators of current times.”
In addition, Nicola has repeatedly been named to Managing IP’s list of the “Top 250 Women in IP”.